Radiation Therapy Is Associated With an Increased Incidence of Cardiac Events in Patients with Small Cell Lung Cancer.
Matthew J Ferris, Renjian Jiang, Madhusmita Behera, Suresh S Ramalingam, Walter J Curran, Kristin A Higgins
Author Information
Matthew J Ferris: Department of Radiation Oncology and Winship Cancer Institute at Emory University, Atlanta, Georgia. Electronic address: mjferri@emory.edu.
Renjian Jiang: Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Madhusmita Behera: Department of Hematology and Medical Oncology, and Winship Cancer Institute at Emory University, Atlanta, Georgia.
Suresh S Ramalingam: Department of Hematology and Medical Oncology, and Winship Cancer Institute at Emory University, Atlanta, Georgia.
Walter J Curran: Department of Radiation Oncology and Winship Cancer Institute at Emory University, Atlanta, Georgia.
Kristin A Higgins: Department of Radiation Oncology and Winship Cancer Institute at Emory University, Atlanta, Georgia.
PURPOSE: Cardiac radiation dose was a predictor of inferior overall survival in the Radiation Therapy Oncology Group 0617 non-small cell lung cancer trial. We examined the association between radiation therapy (RT) and cardiac events (CE) for patients with small cell lung cancer (SCLC). METHODS AND MATERIALS: The US population-based Surveillance, Epidemiology, and End Results Program and Medicare claims databases were queried for rates of CE among patients with SCLC treated with chemotherapy (CTX) ± RT. Propensity score matching (PSM) and multivariate analysis were conducted. Patients were matched for actual/theoretical RT start date (to prevent immortal time bias) and then full PSM balanced clinical characteristics. Cumulative incidence function curves were generated. RESULTS: From 2000 to 2011, 7060 patients were included: 2892 limited-stage SCLC (LS-SCLC) and 4168 extensive-stage SCLC. Grouping LS-SCLC and extensive-stage SCLC together, the incidence of CE for the CTX + RT and CTX-only groups was 44.1% versus 39% at 60 months (P = .008). After PSM (5286 patients), the incidence of CE for the CTX + RT and CTX-only groups was 43% versus 38.6% at 60 months (P = .033). Analysis of only LS-SCLC (2016 patients) demonstrated that the incidence of CE for CTX + RT versus CTX-only groups was 50.3% versus 42% at 60 months (P = .0231). Multivariate analysis again demonstrated an association between CE and RT (hazard ratio 1.20; 95% confidence interval 1.06-1.37; P = .005). After PSM (1614 patients), the incidence of CE for CTX + RT versus CTX-only groups was 51.7% versus 41.6% at 60 months (P = .0042). CONCLUSIONS: Patients with SCLC are at significant risk of developing CE posttreatment; RT is associated with an absolute increase in the rate of CE at 5 years of approximately 5% for all patients with SCLC and up to 10% for patients with LS-SCLC. Cardiac risk management and cardiac-sparing RT techniques should be further evaluated for patients with SCLC.
